JP2011500811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500811A5 JP2011500811A5 JP2010531050A JP2010531050A JP2011500811A5 JP 2011500811 A5 JP2011500811 A5 JP 2011500811A5 JP 2010531050 A JP2010531050 A JP 2010531050A JP 2010531050 A JP2010531050 A JP 2010531050A JP 2011500811 A5 JP2011500811 A5 JP 2011500811A5
- Authority
- JP
- Japan
- Prior art keywords
- clavulanate
- pharmaceutical composition
- composition
- mixture
- clavulanic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 28
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims 22
- 229940090805 clavulanate Drugs 0.000 claims 17
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical group [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 6
- 229960003324 clavulanic acid Drugs 0.000 claims 5
- 239000000945 filler Substances 0.000 claims 5
- 239000000843 powder Substances 0.000 claims 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 239000000314 lubricant Substances 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000000377 silicon dioxide Substances 0.000 claims 3
- 235000012239 silicon dioxide Nutrition 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99607907P | 2007-10-26 | 2007-10-26 | |
| PCT/US2008/012126 WO2009055038A1 (en) | 2007-10-26 | 2008-10-24 | Pharmaceutical formulation of clavulanic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011500811A JP2011500811A (ja) | 2011-01-06 |
| JP2011500811A5 true JP2011500811A5 (enExample) | 2011-12-08 |
Family
ID=40579869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531050A Pending JP2011500811A (ja) | 2007-10-26 | 2008-10-24 | クラブラン酸の医薬品製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090270358A1 (enExample) |
| EP (1) | EP2214680A4 (enExample) |
| JP (1) | JP2011500811A (enExample) |
| KR (1) | KR20100101574A (enExample) |
| CN (1) | CN101918004A (enExample) |
| AU (1) | AU2008317315A1 (enExample) |
| BR (1) | BRPI0818702A2 (enExample) |
| CA (1) | CA2703224A1 (enExample) |
| IL (1) | IL205313A0 (enExample) |
| MX (1) | MX2010004556A (enExample) |
| WO (1) | WO2009055038A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100255099A1 (en) * | 2007-10-26 | 2010-10-07 | Rexahn Pharmaceuticals, Inc. | Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| KR101628095B1 (ko) | 2010-10-18 | 2016-06-08 | 현대자동차 주식회사 | 저압 ｅｇｒ시스템 제어장치 및 방법 |
| CN102058584B (zh) * | 2010-12-30 | 2012-01-25 | 石药集团河北中润制药有限公司 | 克拉维酸钾/微晶纤维素组合物的制备方法 |
| US9751957B2 (en) | 2012-02-15 | 2017-09-05 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| KR102112119B1 (ko) | 2012-10-22 | 2020-05-19 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
| EP2919903B1 (en) | 2012-11-14 | 2020-07-22 | W.R. Grace & CO. - CONN. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
| WO2015153984A2 (en) | 2014-04-04 | 2015-10-08 | Pharmaquest International Center, LLC | Disintegrating monolithic modified release tablets containing quadri-layer extended release granules |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO984B1 (en) * | 1977-10-11 | 1979-12-01 | بيتشام غروب ليمتد | A dry pharmaceutical compound with a suitable dosage unit for oral administration |
| NZ189022A (en) * | 1977-12-08 | 1981-11-19 | Beecham Group Ltd | Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder |
| NZ198241A (en) * | 1980-09-27 | 1983-12-16 | Beecham Group Ltd | Tablet containing amoxycillin and potassium clavulanate |
| GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| GB9405856D0 (en) * | 1994-03-24 | 1994-05-11 | Smithkline Beecham Plc | Pharmaceutical formulation |
| GB9518917D0 (en) * | 1995-09-15 | 1995-11-15 | Smithkline Beecham Plc | Compounds |
| IE990159A1 (en) * | 1999-02-26 | 2000-09-20 | Fuisz Internat Ltd | Storage Stable Amoxycillin and Clavulanate Suspension Composition. |
| BR0013366A (pt) | 1999-08-16 | 2002-07-23 | Revaax Pharmaceuticals Llc | Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama |
| US6489319B2 (en) * | 1999-08-16 | 2002-12-03 | Revaax Pharmaceuticals, Llc | Neurotherapeutic use of carboxypeptidase inhibitors |
| US6426342B2 (en) * | 1999-08-16 | 2002-07-30 | Revaax Pharmaceuticals, Llc | Use of β-lactamase inhibitors as neuroprotectants |
| US7166626B2 (en) | 2001-06-18 | 2007-01-23 | Revaax Pharmaceuticals, Llc | Therapeutic treatment for sexual dysfunction |
| IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
| PE20060489A1 (es) * | 2004-08-13 | 2006-06-19 | Schering Plough Ltd | Formulacion farmaceutica que comprende un antibiotico, un triazol y un corticosteroide |
| DE102006007830A1 (de) * | 2006-02-17 | 2007-08-30 | Grünenthal GmbH | Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure |
| CA2644911A1 (en) * | 2006-03-24 | 2007-10-04 | Panacea Biotec Ltd. | Antibiotic compositions of modified release and process of production thereof |
| US20100255099A1 (en) * | 2007-10-26 | 2010-10-07 | Rexahn Pharmaceuticals, Inc. | Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders |
-
2008
- 2008-10-24 MX MX2010004556A patent/MX2010004556A/es not_active Application Discontinuation
- 2008-10-24 CA CA2703224A patent/CA2703224A1/en not_active Abandoned
- 2008-10-24 EP EP20080842941 patent/EP2214680A4/en not_active Withdrawn
- 2008-10-24 KR KR1020107011374A patent/KR20100101574A/ko not_active Withdrawn
- 2008-10-24 AU AU2008317315A patent/AU2008317315A1/en not_active Abandoned
- 2008-10-24 CN CN2008801224638A patent/CN101918004A/zh active Pending
- 2008-10-24 JP JP2010531050A patent/JP2011500811A/ja active Pending
- 2008-10-24 BR BRPI0818702 patent/BRPI0818702A2/pt not_active IP Right Cessation
- 2008-10-24 WO PCT/US2008/012126 patent/WO2009055038A1/en not_active Ceased
- 2008-10-24 US US12/258,062 patent/US20090270358A1/en not_active Abandoned
-
2010
- 2010-04-25 IL IL205313A patent/IL205313A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500811A5 (enExample) | ||
| JP5750847B2 (ja) | アトルバスタチン経口投与用粒子状医薬組成物 | |
| US8435564B2 (en) | Pharmaceutical compositions comprising brivaracetam | |
| EP2731594B1 (en) | Capsule formulation comprising montelukast and levocetirizine | |
| RS55174B2 (sr) | Formulacija i metod obložene tablete | |
| JP5534004B2 (ja) | 口腔内崩壊錠 | |
| JP5948648B2 (ja) | 安定化されたエペリゾンを含有する徐放性製剤 | |
| WO2010128525A4 (en) | A formulation of ivabradine for treating the cardiovascular disease | |
| JP5614445B2 (ja) | 経口投与用粒子状医薬組成物 | |
| US20140335176A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
| JP6513030B2 (ja) | トホグリフロジンを含有する固形製剤及びその製造方法 | |
| EP2295040B1 (en) | Pharmaceutical compositions of pramipexole | |
| CA2722802C (en) | Granulate comprising escitalopram oxalate | |
| WO2014193528A1 (en) | Amorphous dosage forms and methods | |
| JP2013544272A5 (enExample) | ||
| CN1927185B (zh) | 具速释部分的马来酸曲美布汀缓释片及其制备工艺 | |
| WO2013190151A1 (en) | Pharmaceutical composition comprising fingolimod | |
| WO2012042951A1 (ja) | アトルバスタチン含有医薬錠剤 | |
| WO2014096983A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
| EP2705839B1 (en) | Pharmaceutical composition comprising lacidipine and process of preparation | |
| JP2010516712A5 (enExample) | ||
| WO2025229513A1 (en) | Pharmaceutical composition of resmetirom and process thereof | |
| US10765668B2 (en) | Oral tablet composition comprising dexlansoprazole, oral tablet comprising the same and method for manufacturing the same | |
| RU2545833C1 (ru) | Фармацевтическая композиция с антиишемической и антиоксидантной активностью и способ ее получения | |
| EP2022496A1 (en) | Stable ropinirole compositions |